pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Qfitlia
drug
save

fitusiran

Marketedupdated 3mo ago
by Genzyme Corp
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying fitusiran

  • phase3A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or Brecruitingn=85
  • phase3A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophiliaactive not recruitingn=91
  • phase3Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXactive not recruitingn=281
  • phase4A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumabrecruitingn=20
  • phase3Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or Bactive not recruitingn=32
  • phase2An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or Bcompletedn=34

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 28, 2030
~3.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

  • Dec 7, 2036method-of-use (U-4165)US 11091759
  • Dec 7, 2036method-of-use (U-4165)US 11091759
  • Mar 22, 2033compositionUS 9127274
  • Mar 22, 2033compositionUS 9127274
  • Mar 15, 2033compositionUS 9376680
  • Mar 15, 2033compositionUS 9376680

FDA exclusivities (6)

  • Mar 28, 2032ODE-510Orphan Drug (7y)
  • Mar 28, 2032ODE-511Orphan Drug (7y)
  • Mar 28, 2032ODE-510Orphan Drug (7y)
  • Mar 28, 2032ODE-511Orphan Drug (7y)
  • Mar 28, 2030NCENew Chemical Entity (5y)3.6y
  • Mar 28, 2030NCENew Chemical Entity (5y)3.6y

News(1)

  • After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
    With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
    fiercebiotech · 9d ago
brand
Qfitlia
generic
fitusiran [INN]
indication
Hemophilia A (Factor VIII Deficiency)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?